Wedge Capital Management L L P NC Has $30.21 Million Position in Cencora, Inc. (NYSE:COR)

Wedge Capital Management L L P NC lessened its position in shares of Cencora, Inc. (NYSE:COR - Free Report) by 12.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 134,231 shares of the company's stock after selling 19,122 shares during the quarter. Wedge Capital Management L L P NC owned approximately 0.07% of Cencora worth $30,213,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Financial Advocates Investment Management boosted its stake in Cencora by 4.7% in the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company's stock valued at $220,000 after buying an additional 44 shares in the last quarter. Checchi Capital Advisers LLC boosted its stake in Cencora by 2.2% in the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company's stock valued at $499,000 after buying an additional 48 shares in the last quarter. Valeo Financial Advisors LLC boosted its stake in Cencora by 3.4% in the 2nd quarter. Valeo Financial Advisors LLC now owns 1,566 shares of the company's stock valued at $353,000 after buying an additional 51 shares in the last quarter. Evergreen Capital Management LLC boosted its stake in Cencora by 4.7% in the 2nd quarter. Evergreen Capital Management LLC now owns 1,147 shares of the company's stock valued at $258,000 after buying an additional 52 shares in the last quarter. Finally, Barlow Wealth Partners Inc. boosted its stake in Cencora by 5.4% in the 2nd quarter. Barlow Wealth Partners Inc. now owns 1,339 shares of the company's stock valued at $303,000 after buying an additional 68 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Activity at Cencora

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company's stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now owns 19,980,000 shares in the company, valued at approximately $4,806,388,800. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,473 shares of the business's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the transaction, the executive vice president now directly owns 10,948 shares of the company's stock, valued at approximately $2,656,970.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. 15.80% of the stock is owned by insiders.

Cencora Trading Up 1.0 %

Shares of COR stock traded up $2.25 on Monday, reaching $224.81. 1,603,698 shares of the stock were exchanged, compared to its average volume of 1,415,124. The stock has a market cap of $44.84 billion, a PE ratio of 24.60, a P/E/G ratio of 1.40 and a beta of 0.44. Cencora, Inc. has a one year low of $182.75 and a one year high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The stock has a 50 day moving average price of $232.97 and a 200 day moving average price of $231.31.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, topping analysts' consensus estimates of $3.18 by $0.16. The company had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm's quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.92 earnings per share. Equities research analysts forecast that Cencora, Inc. will post 13.63 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were issued a $0.51 dividend. The ex-dividend date was Friday, August 9th. This represents a $2.04 dividend on an annualized basis and a yield of 0.91%. Cencora's dividend payout ratio is presently 22.32%.

Analyst Ratings Changes

COR has been the topic of several recent analyst reports. Leerink Partners decreased their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating on the stock in a research note on Monday, October 7th. Wells Fargo & Company boosted their price objective on Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a research note on Thursday, August 1st. Bank of America reissued a "neutral" rating and issued a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Robert W. Baird reduced their price objective on Cencora from $287.00 to $283.00 and set an "outperform" rating on the stock in a research note on Friday, September 6th. Finally, JPMorgan Chase & Co. boosted their price objective on Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Cencora currently has a consensus rating of "Moderate Buy" and an average price target of $259.44.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.